Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Trial details
- Registry ID
- NCT05678673
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673 | Exelixis | Phase 3 | Active not recruiting | 2026-12-15Estimated |
| Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940 | Exelixis | Phase 3 | Active not recruiting | 2026-06-16Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |